Article CommentaryCommentary
A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products
Serge Mathonet, Hanns-Christian Mahler, Stefan T. Esswein, Maryam Mazaheri, Patricia W. Cash, Klaus Wuchner, Georg Kallmeyer, Tapan K. Das, Christof Finkler and Andrew Lennard
PDA Journal of Pharmaceutical Science and Technology July 2016, 70 (4) 392-408; DOI: https://doi.org/10.5731/pdajpst.2015.006189
Serge Mathonet
1Global Regulatory Affairs—Biologics CMC, Sanofi R&D, 91385 Chilly-Mazarin, France;
Hanns-Christian Mahler
2Drug Product Services, Lonza AG, 4002 Basel, Switzerland;
Stefan T. Esswein
3NBE Analytical R&D, Abbvie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany;
Maryam Mazaheri
4Analytical Biotechnology, MedImmune, Gaithersburg, MD;
Patricia W. Cash
4Analytical Biotechnology, MedImmune, Gaithersburg, MD;
Klaus Wuchner
5PDMS Analytical Development, Janssen R&D, 8205 Schaffhausen, Switzerland;
Georg Kallmeyer
6Quality Combination Products, Roche, 68305 Mannheim, Germany;
Tapan K. Das
7Biologics Development, Bristol Myers Squibb, Hopewell, NJ;
Christof Finkler
8Analytical Development & Quality Control, Pharma Technical Development Biologics EU, Roche, 4002 Basel, Switzerland; and
Andrew Lennard
9Regional Regulatory Affairs CMC, Amgen Ltd, Uxbridge, UK

Article Information
vol. 70 no. 4 392-408
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online July 18, 2016.
Article Versions
- previous version (April 18, 2016 - 18:05).
- You are viewing the most recent version of this article.
Copyright & Usage
© PDA, Inc. 2016
Author Information
- Serge Mathonet1,*,
- Hanns-Christian Mahler2,
- Stefan T. Esswein3,
- Maryam Mazaheri4,
- Patricia W. Cash4,
- Klaus Wuchner5,
- Georg Kallmeyer6,
- Tapan K. Das7,
- Christof Finkler8 and
- Andrew Lennard9
- 1Global Regulatory Affairs—Biologics CMC, Sanofi R&D, 91385 Chilly-Mazarin, France;
- 2Drug Product Services, Lonza AG, 4002 Basel, Switzerland;
- 3NBE Analytical R&D, Abbvie Deutschland GmbH & Co. KG, 67061 Ludwigshafen, Germany;
- 4Analytical Biotechnology, MedImmune, Gaithersburg, MD;
- 5PDMS Analytical Development, Janssen R&D, 8205 Schaffhausen, Switzerland;
- 6Quality Combination Products, Roche, 68305 Mannheim, Germany;
- 7Biologics Development, Bristol Myers Squibb, Hopewell, NJ;
- 8Analytical Development & Quality Control, Pharma Technical Development Biologics EU, Roche, 4002 Basel, Switzerland; and
- 9Regional Regulatory Affairs CMC, Amgen Ltd, Uxbridge, UK
- ↵* Corresponding Author: e-mail: Serge.Mathonet{at}sanofi.com; telephone: +33 6 73 23 26 85.
Cited By...
This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.
- Wei Wang, Christopher J. RobertsInternational Journal of Pharmaceutics 2018 550 1-2
- Jinjiang Li, Mary E. Krause, Xiaodong Chen, Yuan Cheng, Weiguo Dai, John J. Hill, Min Huang, Susan Jordan, Daniel LaCasse, Linda Narhi, Evgenyi Shalaev, Ian C. Shieh, Justin C. Thomas, Raymond Tu, Songyan Zheng, Lily ZhuThe AAPS Journal 2019 21 3
- Eduard Trenkenschuh, Maximilian Richter, Eilien Heinrich, Marcus Koch, Gregor Fuhrmann, Wolfgang FriessAdvanced Healthcare Materials 2022 11 5
- Julia Gross-Rother, Michaela Blech, Eduard Preis, Udo Bakowsky, Patrick GaridelPharmaceutics 2020 12 11
- Ruta Mockute, Sameen Desai, Sujan Perera, Bruno Assuncao, Karolina Danysz, Niki Tetarenko, Darpan Gaddam, Danielle Abatemarco, Mark Widdowson, Sheryl Beauchamp, Salvatore Cicirello, Edward MinglePharmaceutical Medicine 2019 33 2
- Roman Mathaes, Linda Narhi, Andrea Hawe, Anja Matter, Karoline Bechtold-Peters, Sophia Kenrick, Sambit Kar, Olga Laskina, John Carpenter, Richard Cavicchi, Ellen Koepf, E. Neil Lewis, Rukman De Silva, Dean RippleThe AAPS Journal 2020 22 1
- Dominique Ditter, Alejandra Nieto, Hanns-Christian Mahler, Holger Roehl, Michael Wahl, Joerg Huwyler, Andrea AllmendingerJournal of Pharmaceutical Sciences 2018 107 2
- Maryam ShahInternational Journal of Pharmaceutics 2018 552 1-2
- Vaida Linkuvienė, Emma L. Ross, Lindsey Crawford, Sarah E. Weiser, Damen Man, Stephen Kay, Parag Kolhe, John F. CarpenterJournal of Pharmaceutical Sciences 2022 111 4
- Margaret N. Ruesch, Luca Benetti, Eileen Berkay, David J. Cirelli, Neha Frantz, Martin H. Gastens, Wayne P. Kelley, Juliana Kretsinger, Mike Lewis, Shawn Novick, Barbara Rellahan, Laura Pack, Corné J.M. Stroop, Ann Subashi, Ping Yin, Ming Zeng, John StultsJournal of Pharmaceutical Sciences 2021 110 2
- Ema Valentina Brovč, Janez Mravljak, Roman Šink, Stane PajkEuropean Journal of Pharmaceutics and Biopharmaceutics 2020 154
- Tapan K. Das, Alavattam Sreedhara, James D. Colandene, Danny K. Chou, Vasco Filipe, Christoph Grapentin, Jim Searles, Twinkle R. Christian, Linda O. Narhi, Wim JiskootJournal of Pharmaceutical Sciences 2022 111 4
- Kohei Soeda, Masakazu Fukuda, Masaya Takahashi, Hirotaka Imai, Kengo Arai, Satoshi Saitoh, Ravuri S.K. Kishore, Nuria Sancho Oltra, Jeremy Duboeuf, Daisuke Hashimoto, Yuji YamanakaJournal of Pharmaceutical Sciences 2022 111 8
- Rameez Kagdi, Kim Le, Dany Doucet, James Ludlow, Joseph V. RinellaJournal of Pharmaceutical Sciences 2020 109 11
- Veronika Hampl, Xinghua Guo, Christian Ehrenstrasser, Martin Viertler, Lucy Rayner, Giusy Campanelli, Reinhard Schipflinger, Karine Thewes, Alessandra Cerreti, Stephan Boehm, Corinna SondereggerJournal of Pharmaceutical Sciences 2018 107 6
- Nidhi Doshi, Kyle Ritchie, Tamanna Shobha, Jamie Giddings, Kathrin Gregoritza, Rosalynn Taing, Stephen Rumbelow, Jeff Chu, Anthony Tomlinson, Aadithya Kannan, Miguel Saggu, Si Kai Cai, Victor Nicoulin, Wenqiang Liu, Steve Russell, Lin Luis, Sandeep YadavPharmaceutical Research 2021 38 9
- Yihua Bruce Yu, Marc B. Taraban, Weizhen Wang, Katharine T. BriggsTrends in Biotechnology 2017 35 12
- Dhananjay Jere, Ahmad S. Sediq, Jörg Huwyler, Ilona Vollrath, Markus Kardorff, Hanns-Christian MahlerJournal of Pharmaceutical Sciences 2021 110 5
- Maciej Stawny, Aleksandra Gostyńska, Malwina Nadolna, Anna JelińskaPharmaceutics 2020 12 3
- Aadithya Kannan, Jamie Giddings, Shrenik Mehta, Tiffany Lin, Anthony Tomlinson, Kyle Ritchie, Ian Shieh, Miguel Saggu, Nidhi DoshiPharmaceutical Research 2022 39 3
- Nidhi Doshi, Karen Rutherford, Asil NajjarJournal of Pharmaceutical Sciences 2021 110 2
- Katharine T. Briggs, Marc B. Taraban, Weizhen Wang, Y. Bruce YuAAPS PharmSciTech 2019 20 5
- Rana Fayek, Mostafa Soleyman, Wim Jiskoot, Mirjam CrulEuropean Journal of Oncology Pharmacy 2021 4 3
- Maryam Mazaheri, Miguel Saggu, Klaus Wuchner, Atanas V. Koulov, Felix Nikels, Pascal Chalus, Tapan K. Das, Patricia W. Cash, Christof Finkler, Sophia V. Levitskaya-Seaman, John Case, Jonny Parsons, Kristen GonzalezJournal of Pharmaceutical Sciences 2024 113 3
- Mechanism of Protein–PDMS Visible Particles Formation in Liquid Vial Monoclonal Antibody FormulationKohei Soeda, Kengo Arai, Tetsuya Yamamoto, Katsuya Ofuji, Masakazu Fukuda, Daisuke Hashimoto, Yuji YamanakaJournal of Pharmaceutical Sciences 2023 112 3
- Srivalli N. Telikepalli, Michael J. Carrier, Dean C. Ripple, Greg Barnett, Ashwinkumar Bhirde, Donna Bolton, George M. Bou-Assaf, Erica Ferrari, Scott Leigh, Sophia Levitskaya-Seaman, Tim Menzen, Felix Nikels, Anna Riley, Miguel Saggu, Neha Sahni, Eric Vernooij, Klaus WuchnerAAPS PharmSciTech 2022 24 1
- Mark Cornell Manning, Ryan E. Holcomb, Robert W. Payne, Joshua M. Stillahn, Brian D. Connolly, Derrick S. Katayama, Hongcheng Liu, James E. Matsuura, Brian M. Murphy, Charles S. Henry, Daan J. A. CrommelinPharmaceutical Research 2024 41 7
- Frank Liu, Richard HutchinsonCurrent Research in Toxicology 2024 7
- Miguel Saggu, George M. Bou-Assaf, Reinhard Bucher, Ivan L. Budyak, Jakob Buecheler, Shawn Cao, Minna Groenning, Emon Khan, Stanley C. Kwok, Shalini Minocha, Karthik Pisupati, Vinay Radhakrishnan, Nicoline Videbæk, Dennis T. Yang, Bin Zhang, Linda O. NarhiJournal of Pharmaceutical Sciences 2024 113 5
- Frank LiuRegulatory Toxicology and Pharmacology 2024 153
- Alexandre Jambon, Marie Forat, Chloé Marchand, Corinne Morel, Camille Merienne, Samira Filali, Fabrice PirotEuropean Journal of Hospital Pharmacy 2024
- Steven Messick, Miguel Saggu, Anacelia Ríos Quiroz2020 35
- Ian Aled Jones, Alex Bird, Nathaniel LochrieEJPPS EUROPEAN JOURNAL OF PARENTERAL AND PHARMACEUTICAL SCIENCES 2021
- Hiroko Shibata, Satoshi Saitoh, Masato Kiyoshi, Yu Hayashi, Kazue Inaba, Shinji Katsura, Maho Sakurai, Yuka Komine, Shinji Okabe, Naomi Ohbayashi, Youko Kita, Hirokazu Kito, Masako Nakano, Kana Miyamoto, Akira Maruyama, Yuya Miyahara, Masanori Noda, Yasuyo Nozawa, Kazutaka Shimbo, Shota Kojima, Shinya Honda, Tetsuo Torisu, Susumu Uchiyama, Akiko Ishii-WatabeThe AAPS Journal 2025 27 3
In This Issue
PDA Journal of Pharmaceutical Science and Technology
Vol. 70, Issue 4
July/August 2016
A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products
Serge Mathonet, Hanns-Christian Mahler, Stefan T. Esswein, Maryam Mazaheri, Patricia W. Cash, Klaus Wuchner, Georg Kallmeyer, Tapan K. Das, Christof Finkler, Andrew Lennard
PDA Journal of Pharmaceutical Science and Technology Jul 2016, 70 (4) 392-408; DOI: 10.5731/pdajpst.2015.006189
A Biopharmaceutical Industry Perspective on the Control of Visible Particles in Biotechnology-Derived Injectable Drug Products
Serge Mathonet, Hanns-Christian Mahler, Stefan T. Esswein, Maryam Mazaheri, Patricia W. Cash, Klaus Wuchner, Georg Kallmeyer, Tapan K. Das, Christof Finkler, Andrew Lennard
PDA Journal of Pharmaceutical Science and Technology Jul 2016, 70 (4) 392-408; DOI: 10.5731/pdajpst.2015.006189
Jump to section
- Article
- Abstract
- 1. Problem Statement
- 2. Visual Inspection at End of Drug Product Manufacturing—100% Inspection Followed by Sampling Inspection
- 3. QC Sample Testing
- 4. Control of Visible Particles in Lyophilized Products
- 5. Particle Identification and Characterization
- 6. Patient Safety
- 7. Conclusions
- Conflict of Interest Declaration
- Acknowledgments
- Appendix 1: Inspector Certification
- Appendix 2: Risk Assessment of Visible Particles
- References
- Figures & Data
- References
- Info & Metrics
Related Articles
- No related articles found.
Cited By...
- Definition of Particle Visibility Threshold in Parenteral Drug Products--Towards Standardization of Visual Inspection Operator Qualification
- Comparing visual inspection methods for parenteral products in hospital pharmacy: between reliability, cost, and operator formation considerations
- Identification and Root Cause Analysis of the Visible Particles Commonly Encountered in the Biopharmaceutical Industry
- Characterization of a Novel Particle in a Pharmaceutical Drug Product
- Development and Qualification of Visible Particle Load Analysis Methods for Injectable Drug Product Primary Packaging Components
- Micro-Flow Imaging: Estimation of the Contribution of Key Factors to the Variability of Subvisible Particle Count Measurement by a Nested Statistical Analysis
- Development of Protein-Like Reference Material for Semiquantitatively Monitoring Visible Proteinaceous Particles in Biopharmaceuticals
- Achieving "Zero" Defects for Visible Particles in Injectables